Todays Report: Today, Mizuho Trust & Banking Co. Ltd. invests in GlaxoSmithKline PLC (GSK) Shares

Today, Mizuho Trust & Banking Co. Ltd. invests in GlaxoSmithKline PLC (GSK) Shares

Mizuho Trust & Banking Co. Ltd. raised its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 22.8% during the third quarter, Holdings Channel reports. The fund owned 115,600 shares of the pharmaceutical company’s stock after buying an additional 21,500 shares during the period. Mizuho Trust & Banking Co. Ltd.’s holdings in GlaxoSmithKline PLC were worth $4,986,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. FMR LLC increased its stake in GlaxoSmithKline PLC by 29.8% in the second quarter. FMR LLC now owns 20,701,378 shares of the pharmaceutical company’s stock valued at $897,198,000 after buying an additional 4,757,238 shares during the last quarter. Thornburg Investment Management Inc. increased its stake in GlaxoSmithKline PLC by 188.7% in the second quarter. Thornburg Investment Management Inc. now owns 1,025,410 shares of the pharmaceutical company’s stock valued at $44,441,000 after buying an additional 670,284 shares during the last quarter. Ameriprise Financial Inc. increased its stake in GlaxoSmithKline PLC by 24.7% in the second quarter. Ameriprise Financial Inc. now owns 3,038,134 shares of the pharmaceutical company’s stock valued at $132,800,000 after buying an additional 602,693 shares during the last quarter. Chartwell Investment Partners LLC increased its stake in GlaxoSmithKline PLC by 519.1% in the second quarter. Chartwell Investment Partners LLC now owns 561,735 shares of the pharmaceutical company’s stock valued at $24,346,000 after buying an additional 471,005 shares during the last quarter. Finally, Nationwide Fund Advisors acquired a new stake in GlaxoSmithKline PLC during the third quarter valued at about $15,399,000. 8.51% of the stock is owned by institutional investors and hedge funds.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded up 0.16% during midday trading on Thursday, reaching $38.10. The company had a trading volume of 4,103,422 shares. GlaxoSmithKline PLC has a 12-month low of $37.65 and a 12-month high of $45.58. The firm has a market capitalization of $92.70 billion, a price-to-earnings ratio of 250.66 and a beta of 0.93. The company has a 50 day moving average of $40.30 and a 200 day moving average of $42.42.

The business also recently announced a dividend, which will be paid on Thursday, January 12th. Stockholders of record on Friday, November 4th will be paid a $0.459 dividend. The ex-dividend date of this dividend is Wednesday, November 2nd. GlaxoSmithKline PLC’s dividend payout ratio is currently 1,533.33%.

Several analysts recently issued reports on GSK shares. Bank of America Corp. reissued a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a research report on Tuesday, September 20th. Citigroup Inc. reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, August 10th. BNP Paribas downgraded shares of GlaxoSmithKline PLC from a “neutral” rating to an “underperform” rating in a report on Tuesday, September 13th. Beaufort Securities reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, August 2nd. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Friday, September 16th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. GlaxoSmithKline PLC presently has an average rating of “Hold” and a consensus target price of $48.20.

In related news, major shareholder Plc Glaxosmithkline bought 66,500 shares of the business’s stock in a transaction dated Monday, October 24th. The shares were purchased at an average cost of $14.00 per share, with a total value of $931,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is owned by insiders.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Related posts

Leave a Comment